Major Changes Coming with IVDR

In Vitro Diagnostic Regulation (IVDR) Changes 2021

Listen to this IVDR highlight from RCA Radio where Seyed Khorashahi breaks down the EU’s move from list-based IVD device classifications to a rule-based IVD medical device classification, resulting in four new device classes.
 

 

Listen to the entire episode where we go over all of the important things happening in the Medical Device industry here.


Need help with your transition to the IVDR? Contact Us Now →


Device Classification Changes

  • List-based Classification to a Rule-Based 
    • Class A (lowest risk) to class D (highest risk), where class B, C, and D would require Notified Body (NB) involvement.
  • MDGC 202- 16 Guidance on Classification for in vitro diagnostic Medical Devices under Regulation (EU) 2017/746.

Lifecycle Approach

  • Establishment and Demonstration of effective Quality Management Systems (QMS).
  • More stringent requirements for clinical evidence that demonstrates conformity.
  • Post-Market Performance monitoring and reporting requirements.
  • Introduction of Unique Device Identifiers (UDIs) for improved traceability.

Supply Chain Oversight

  • Regulations covering the entire supply chain.
    • Economic Operators
      • Importers
      • Distributors
      • Authorized Representatives
  • Notified Bodies have discretionary authority to audit suppliers and subcontractors

About Seyed Khorashahi 

Seyed Khorashahi has more than 25 years’ experience leading R&D teams in all aspects of developing safety-critical medical devices. He has held leadership positions at Covidien (Medtronic), Baxter, and Beckman Coulter, Inc., and has an extensive background in medical device product development, quality systems, regulatory affairs, and mergers and acquisitions. Other core competencies include engineering and business strategy.

Seyed has significant domain expertise not only in FDA and EU standards but also in software systems and hardware development for medical devices. A passionate innovator, he is a skilled collaborator as well, with recognized leadership capabilities and a relentless drive to overcome technical and business challenges. He is an influencer, consensus-builder, and a leader with success in establishing and managing relationships with external partners, executives, and internal multi-functional teams.

 

About RCA

pharmaceutical consultantsRegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies.

 

As your partners, we can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

 

To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

 

News

Parenteral Products Sterilization and Extractables Evaluation to Help Ensure Drug Safety...
Read More

News

Parenteral Products Sterilization and Extractables Evaluation to Help Ensure Drug Safety...
Read More

News

Our website uses cookies to give you the best possible experience.

By continuing to use this site, you agree to the use of cookies.
Continue